{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-241312","form_type":"8-K","ticker":null,"cik":"0001652724","company_name":"Lucira Health, Inc.","filed_at":"2023-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.725174+00:00","generated_at":"2026-06-10T09:13:45.242266+00:00","sec_items":["1.03","8.01","3.03","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Bankruptcy court confirms Lucira Health's Chapter 11 liquidation plan; equity cancelled","bullets":["Confirmation Order entered Sept 19, 2023; all 41,763,433 common shares will be cancelled on Effective Date.","Pfizer purchased substantially all assets in April 2023; proceeds go to a liquidating trust for allowed claims.","Brian Ryniker appointed Liquidating Trustee; CEO, CFO, and one director resign on Effective Date.","Holders of equity interests receive no distribution under the liquidation plan.","Company holds ~$565k employee retention credit claim; August 2023 monthly operating report filed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-241312","json":"https://secwatch.observer/filing/0001193125-23-241312.json","markdown":"https://secwatch.observer/filing/0001193125-23-241312.md","text":"https://secwatch.observer/filing/0001193125-23-241312.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652724/000119312523241312/0001193125-23-241312-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652724/000119312523241312/d538189d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T09:13:45.242266+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44f85f9ea0d6ec5a53062273b95c02a54eef4322","claim":"Lucira Health, Inc. entered chapter 11 in United States Bankruptcy Court for the District of Delaware (petition 2023-02-22).","evidence_excerpt":"On February 22, 2023, Lucira Health, Inc. (the “Company” or the “Debtor”) filed a voluntary petition (Case No. 23-10242) for relief under Chapter 11 of title 11 the United States Bankruptcy Code","evidence_source":"SEC 8-K Item 1.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652724/000119312523241312/0001193125-23-241312-index.htm","confidence":0.9,"family_label":"Distress & Bankruptcy","details":[{"label":"Proceeding","value":"chapter 11"},{"label":"Court","value":"United States Bankruptcy Court for the District of Delaware"},{"label":"Petition","value":"2023-02-22"}],"fact_type":"distress_event"},{"claim_id":"1861dc2b3e","claim":"Michael Wyse resigned as member of the Board of Directors at Lucira Health, Inc..","evidence_excerpt":"Pursuant to the terms of the Chapter 11 Plan, on the Effective Date, Brian Ryniker will be appointed as the Liquidating Trustee and representative of the Debtor’s Estate, and Erik T. Engelson, President, Chief Executive Officer and member of the Company’s Board of Directors (the “Board”), Michael Wyse, member of the Board, and Richard Narido, Chief Financial Officer, will each be deemed to have resigned from their respective positions as directors and officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652724/000119312523241312/0001193125-23-241312-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"84d93afa6f","claim":"Erik T. Engelson resigned as President, Chief Executive Officer and member of the Board of Directors at Lucira Health, Inc..","evidence_excerpt":"Pursuant to the terms of the Chapter 11 Plan, on the Effective Date, Brian Ryniker will be appointed as the Liquidating Trustee and representative of the Debtor’s Estate, and Erik T. Engelson, President, Chief Executive Officer and member of the Company’s Board of Directors (the “Board”), Michael Wyse, member of the Board, and Richard Narido, Chief Financial Officer, will each be deemed to have resigned from their respective positions as directors and officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652724/000119312523241312/0001193125-23-241312-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President, Chief Executive Officer and member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"b6de2d3e4a","claim":"Brian Ryniker was appointed as Liquidating Trustee at Lucira Health, Inc..","evidence_excerpt":"Pursuant to the terms of the Chapter 11 Plan, on the Effective Date, Brian Ryniker will be appointed as the Liquidating Trustee and representative of the Debtor’s Estate, and Erik T. Engelson, President, Chief Executive Officer and member of the Company’s Board of Directors (the “Board”), Michael Wyse, member of the Board, and Richard Narido, Chief Financial Officer, will each be deemed to have resigned from their respective positions as directors and officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652724/000119312523241312/0001193125-23-241312-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Liquidating Trustee"}],"fact_type":"executive_change"},{"claim_id":"e9ce71019c","claim":"Richard Narido resigned as Chief Financial Officer at Lucira Health, Inc..","evidence_excerpt":"Pursuant to the terms of the Chapter 11 Plan, on the Effective Date, Brian Ryniker will be appointed as the Liquidating Trustee and representative of the Debtor’s Estate, and Erik T. Engelson, President, Chief Executive Officer and member of the Company’s Board of Directors (the “Board”), Michael Wyse, member of the Board, and Richard Narido, Chief Financial Officer, will each be deemed to have resigned from their respective positions as directors and officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652724/000119312523241312/0001193125-23-241312-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}